OncLive TV

Jacob G. Scott, MD, DPhil, discusses the incorporation of genomic-adjusted radiation dose–based radiotherapy dosing in oncology.

Pradnya D. Patil, MD, FACP, discusses recent developments with targeted therapies in lung cancer.

Wassim Abida, MD, PhD, discusses future research directions in the treatment of patients with metastatic castration-resistant prostate cancer.

Edward Chu, MD, MMS, discusses ongoing efforts to address disparities in lung cancer at Montefiore and Albert Einstein College of Medicine.

Natasha Garg, DO, discusses the emergence of antiandrogen agents in the nonmetastatic castration-resistant prostate cancer treatment paradigm.

Jonathan W. Goldman, MD, discusses key takeaways from the phase 3 CASPIAN trial in patients with extensive-stage small cell lung cancer.

Martin Dietrich, MD, PhD, shares how he navigates the non–small cell lung cancer (NSCLC) treatment landscape.

Ramez N. Eskander, MD, discusses the utility of lymphadenectomy in patients with endometrial cancer.

Leanne Burnham, PhD, discusses the correlation between HER2 positivity and race in patients with prostate cancer.

Chad V. Pecot, MD, discusses addressing mechanisms of resistance with new targeted therapies in non–small cell lung cancer.

Neeraj Agarwal, MD, discusses the efficacy of intensified androgen deprivation therapy in patients with newly diagnosed, metastatic, hormone-sensitive prostate cancer.

Rachel N. Grisham, MD, discusses the rationale to explore the combination of VS-6766 and defactinib in patients with low-grade serous ovarian cancer.

Susan F. Slovin, MD, PhD, discusses selecting among available treatment options for patients with metastatic castration-sensitive prostate cancer.

Brian A. Van Tine, MD, PhD, discusses outcomes with catequentinib in the treatment of patients with synovial sarcoma.

Marwan Fakih, MD, discusses efficacy reported with regorafenib plus nivolumab in patients with mismatch repair–proficient and microsatellite stable metastatic colorectal cancer.

James Stevenson, MD, discusses ongoing research efforts that are generating excitement in extensive-stage small cell lung cancer.

Neal D. Shore, MD, FACS, medical director of the Carolina Urologic Research Center, discusses the clinical utility of piflufolastat F 18 in identifying suspected metastasis or recurrence of prostate cancer.

Jennifer Litton, MD, discusses the safety of talazoparib (Talzenna) in the neoadjuvant treatment of patients with germline BRCA1/2-positive, early-stage HER2-negative breast cancer.

Scott Tagawa, MD, MS, FACP, discuss the integration of targeted agents in prostate cancer.

Riad Salem, MD, discusses the history of TheraSphere™ Yttrium-90 in metastatic colorectal cancer.

Hans Hammers, MD, PhD,discusses the safety profile of lenvatinib in combination with pembrolizumab in renal cell carcinoma.

Pauline Funchain, MD, discusses the rationale for the phase 3 SWOG S1404 trial in high-risk resected melanoma.

Julie M. Vose, MD, MBA, discusses the potential utility of CAR T-cell therapy across the non-Hodgkin lymphoma paradigm.

Jonathan Spicer, MD, PhD, discusses the efficacy observed with neoadjuvant nivolumab plus platinum-doublet chemotherapy in patients with resectable non–small cell lung cancer.

Lyndsay Willmott, MD, discusses the expanding role for genomic testing in ovarian cancer.

Michael J. Morris, MD, discusses findings from the phase 2 TheraP study, and how they led to the development of the phase 3 VISION trial in metastatic castration-resistant prostate cancer.

Earle Burgess, MD, discusses the integration of PARP inhibitors in advanced prostate cancer.

Bradley J. Monk, MD, FACS, FACOG, discusses the utility of PARP inhibitors as frontline maintenance therapy in ovarian cancer.

Rachel N. Grisham, MD, discusses rationale for evaluating binimetinib as a treatment option for patients with low-grade serous ovarian cancer.

Anita Kumar, MD, discusses future directions with pirtobrutinib in mantle cell lymphoma.